• 1.

    Ministério da Saúde, 2010. Manual de Vigilância da Leishmaniose Tegumentar Americana. Saúde SdVe, ed: Editora MS, 78.

  • 2.

    Goodwin LG, 1995. Pentostan (sodium stibogluconate); a 50-year personal reminiscence. Trans R Soc Trop Med Hyg 89: 339341.

  • 3.

    Herwaldt BL, 1999. Leishmaniasis. Lancet 354: 11911199.

  • 4.

    Andersen EMC-SM, Llanos-Cuentos A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD, 2005. Comparison of meglumine antimoniate and pentamidine for perureian cutaneous leishmaniasis. J Trop Med Hyg 72: 133137.

    • Search Google Scholar
    • Export Citation
  • 5.

    Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Gasser RA Jr, Magill AJ, Endy TP, Coyne PE, Grogl M, Benson PM, Beard JS, Tally JD, Gambel JM, Kreutzer RD, Oster CN, 1998. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 27: 14571464.

    • Search Google Scholar
    • Export Citation
  • 6.

    Ribeiro AL, Drummond JB, Volpini AC, Andrade AC, Passos VM, 1999. Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Braz J Med Biol Res 32: 297301.

    • Search Google Scholar
    • Export Citation
  • 7.

    DAIDS, 2004. Division of AIDS table for grading the severity of adult and pediatric adverse events: DAIDS Regulatory Support Center.

  • 8.

    Romero GA, Mendonça S, Schubach A, Noronha E, Matos M, Dietze R, 2006. O desafio para a realização de ensaios clínicos em leishmaniose tegumentar. Revista da Sociedade Brasileira de Medicina Tropical 39 (III Suppl): 100103.

    • Search Google Scholar
    • Export Citation
  • 9.

    Schubach AO, Marzochi KBF, Moreira JS, Schubach TMP, Araújo ML, Francesconi-do-Vale AC, Passos SRL, Marzochi MC, 2005. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Rev Soc Bras Med Trop 38: 213217.

    • Search Google Scholar
    • Export Citation
  • 10.

    Marsden P, Llanos Cuentas E, Lago E, Cuba C, Barreto A, Costa J, Jones T, 1984. Human mucocutaneous leishmaniasis in Tres Bracos, Bahia - Brazil. An area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution. Rev Soc Bras Med Trop 17: 179186.

    • Search Google Scholar
    • Export Citation
  • 11.

    Ampuero J, 2009. Efficacy and safety of low-dose pentavalent antimonial for treatment of cutaneous leishmaniasis by Leishmania (Viannia) braziliensis in Bahia, Brazil: a randomized clinical trial. Thesis, Núcleo de Medicina Tropical. Brasília - DF: Universidade de Brasília, 260.

    • Search Google Scholar
    • Export Citation
  • 12.

    Schubach A, Marzochi MC, Cuzzi-Maya T, Oliveira AV, Araújo ML, Oliveira AL, Pacheco RS, Momen H, Conceição-Silva F, Coutinho SG, Marzochi KB, 1998. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am J Trop Med Hyg 58: 824827.

    • Search Google Scholar
    • Export Citation
  • 13.

    de Paula CDSJ, Cardoso DR, Sampaio RN, 2003. A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis. Rev Soc Bras Med Trop 36: 365371.

    • Search Google Scholar
    • Export Citation
  • 14.

    Saldanha AC, Romero GA, Guerra C, Merchan-Hamann E, Macedo VO, 2000. Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity. Rev Soc Bras Med Trop 33: 383388.

    • Search Google Scholar
    • Export Citation
  • 15.

    Soto J, Buffet P, Grogl M, Berman J, 1994. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 50: 107111.

    • Search Google Scholar
    • Export Citation
  • 16.

    de Camargo Ferreira EV, de Oliveira Schubach A, Valete-Rosalino CM, de Souza Coutinho R, Conceicao-Silva F, de Matos Salgueiro M, Rosandiski Lyra M, Soares Moreira J, Azeredo-Coutinho RB, Fernandes Pimentel MI, Roberto Mortari S, de Fatima Madeira M, Pereira Quintella L, Baptista C, de Almeida Marzochi MC, 2010. American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil. J Am Geriatr Soc 58: 614616.

    • Search Google Scholar
    • Export Citation
  • 17.

    Claros P, Wienberg P, Gonzalez MA, Claros A, Claveria MA, Lopez P, 1996. Intralesional treatment of cutaneous leishmaniasis: a report of two cases. Acta Otorrinolaringol Esp 47: 6770.

    • Search Google Scholar
    • Export Citation
  • 18.

    Harms G, Chehade AK, Douba M, Roepke M, Mouakeh A, Rosenkaimer F, Bienzle U, 1991. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 85: 214216.

    • Search Google Scholar
    • Export Citation
  • 19.

    Sharquie KEA-TK, Chu AC, 1988. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 119: 5357.

    • Search Google Scholar
    • Export Citation
  • 20.

    Tallab TM, Bahamdam KA, Mirdad S, Johargi H, Mourad MM, Ibrahim K, el Sherbini AH, Karkashan E, Khare AK, Jamal A, 1996. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol 35: 594597.

    • Search Google Scholar
    • Export Citation
  • 21.

    Schubach A, Haddad F, Oliveira-Neto MP, Degrave W, Pirmez C, Grimaldi G Jr, Fernandes O, 1998. Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J Infect Dis 178: 911914.

    • Search Google Scholar
    • Export Citation
  • 22.

    Mendonça MG, De Brito ME, Rodrigues EH, Bandeira V, Jardim ML, Abath FG, 2004. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 189: 10181023.

    • Search Google Scholar
    • Export Citation
  • 23.

    Schubach A, Cuzzi-Maya T, Oliveira AV, Sartori A, de Oliveira-Neto MP, Mattos MS, Araujo ML, Souza WJ, Haddad F, Perez Mde A, Pacheco RS, Momen H, Coutinho SG, de Almeida Marzochi MC, Marzochi KB, da Costa SC, 2001. Leishmanial antigens in the diagnosis of active lesions and ancient scars of American tegumentary leishmaniasis patients. Mem Inst Oswaldo Cruz 96: 987996.

    • Search Google Scholar
    • Export Citation
  • 24.

    Wortmann GW, Miller RS, Blazes D, Oster CN, 2000. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis 31: 199201.

  • 25.

    Marsden PD, Tada MS, Barreto AC, Cuba CC, 1984. Spontaneous healing of Leishmania braziliensis braziliensis skin ulcers. Trans R Soc Trop Med Hyg 78: 561562.

    • Search Google Scholar
    • Export Citation
  • 26.

    Zajtchuk JT, Netto EM, Grogl M, Neafie RC, Hessel CR, de Magalhaes AV, Marsden PD, 1989. Mucosal leishmaniasis in Brazil. Laryngoscope 99: 925939.

 
 
 

 

 
 
 

 

 

 

 

 

 

Intralesional Meglumine Antimoniate for Treatment of Cutaneous Leishmaniasis Patients with Contraindication to Systemic Therapy from Rio de Janeiro (2000 to 2006)

View More View Less
  • Leishmaniasis Surveillance Laboratory, and Epidemiology Laboratory, Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; Bonsucesso Federal Hospital, Ministry of Health, Rio de Janeiro, Brazil; Immunoparasitology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; Otorrhynolaringology and Ophtalmology Department, Rio de Janeiro Federal University, Rio de Janeiro, Brazil; Scientific and Technology Development National Council, Brasília, Brazil

We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in 24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with contraindication to systemic therapy. Each treatment consisted of one to four intralesional applications of MA at 15-day intervals. Patients' age ranged from 3 to 90 years; fourteen were females. Intralesional treatment in the absence of any relevant toxicity was successful in 20 (83.3%) patients. Three patients required additional treatment with amphotericin B and one required systemic MA. None of the patients developed mucosal lesions when followed up to 60 months. Intralesional MA is an effective and less toxic alternative treatment of patients with CL and contraindication to systemic therapy.

Author Notes

*Address correspondence to Cláudia Maria Valete-Rosalino, Fundação Oswaldo Cruz - Laboratório de Vigilância em Leishmanioses, Av. Brasil, 4365 – Manguinhos, Rio de Janeiro, RJ, Brazil 21045900. E-mails: claudia.valete@ipec.fiocruz.br

Financial support: This study was supported by the Rio de Janeiro Municipal Health Secretariat (RJ/FIOCRUZ accord), FIOCRUZ, FAPERJ, CNPq, and PAPES4/FIOCRUZ.

Authors' addresses: Érica de Camargo Ferreira e Vasconcellos, Maria Inês Fernandes Pimentel, Armando de Oliveira Schubach, Mariza de Matos Salgueiro, João Soares Moreira, Maria de Fátima Madeira, Cibele Baptista, and Cláudia Maria Valete-Rosalino, Fundação Oswaldo Cruz – Laboratório de Vigilância em Leishmanioses Rio de Janeiro, Rio de Janeiro, Brazil, E-mails: erica.vasconcellos@ipec.fiocruz.br, maria.pimentel@ipec.fiocruz.br, armando.schubach@ipec.fiocruz.br, mariza.salgueiro@ipec.fiocruz.br, joao.moreira@ipec.fiocruz.br, fatima.madeira@ipec.fiocruz.br, cibele.baptista@ipec.fiocruz.br, and claudia.valete@ipec.fiocruz.br. Raquel de Vasconcellos Carvalhaes de Oliveira, FIOCRUZ – Laboratório de Epidemiologia Rio de Janeiro, Rio de Janeiro, Brazil, E-mail: raquel.vasconcellos@ipec.fiocruz.br. Rilza Beatriz Azeredo-Coutinho, Hospital Federal de Bonsucesso – Dermatologia Rio de Janeiro, Rio de Janeiro, Brazil, E-mail: coutinhob@ymail.com. Fátima da Conceição Silva, Fundação Oswaldo Cruz – IOC Rio de Janeiro, Rio de Janeiro, Brazil, E-mail: fconcei@ioc.fiocruz.br.

Save